Caris Life Sciences Partners with Genentech in $1.1 Billion Oncology Target Discovery Collaboration
核心洞察
Caris Life Sciences (搜索) has entered into a multi-year collaboration with Genentech to identify and validate novel oncology targets in solid tumor tissue using Caris' repository of nearly 500,000 tumor samples.
The agreement provides Caris with $25 million in upfront and near-term payments, plus potential milestone payments of up to $1.1 billion and tiered royalties on net sales.
The collaboration combines Caris' multimodal data and tissue-based discovery platform with Genentech's therapeutic development expertise to advance first-in-class cancer medicines.
Caris Life Sciences (搜索) announced a multi-year collaboration and license agreement with Genentech, a member of the Roche Group, to identify and validate novel oncology targets in solid tumor tissue. The partnership leverages Caris' extensive tumor sample repository and AI-driven discovery platform to advance precision medicine for cancer patients with high unmet clinical needs.
Financial Terms and Structure
Under the agreement terms, Caris is eligible to receive upfront and near-term payments totaling $25 million. The company also stands to earn up to $1.1 billion in potential research, development, commercial and net sales milestone payments, along with potential tiered royalties on net sales of collaboration therapies.
The milestone payments are contingent upon Genentech's discretionary advancement decisions at multiple stages and achievement of development, regulatory, and commercial milestones, with no assurance that any targets will progress through the full pipeline.
Platform Capabilities and Data Assets
Caris brings significant data assets to the collaboration through its extensive repository of nearly 500,000 solid tumor samples, accompanied by matched comprehensive molecular and clinical data. This repository enables sophisticated and flexible target discovery capabilities leveraging both tissue-based and data-centric techniques.
The company's discovery platform utilizes comprehensive molecular profiling through Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms at scale. Caris Discovery (搜索) scientists employ an integrated bioinformatics and wet-lab workflow that combines interrogation of solid tissue and cell-based systems with multimodal data to validate prioritized targets.
Strategic Vision and Leadership Perspectives
"At Caris, we are committed to making precision medicine a reality for all patients. This innovative collaboration with Genentech is specifically designed to identify and validate novel targets in solid tumors," said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris. "By combining Caris' unparalleled multimodal data and tissue-based discovery engine with Genentech's deep expertise in therapeutics development, we hope to enable the development of first-in-class medicines for cancer patients."
Boris L. Zaïtra, Head of Roche Corporate Business Development, emphasized the strategic importance of the partnership: "Roche and Genentech are driven by a profound vision - a future where cancer can be cured. We have successfully led many fundamental scientific advances in oncology. As we continue to bring forth transformative medicines, collaborations with partners such as Caris allow us to pursue future innovation for patients with unmet needs."
Technology Integration and Discovery Approach
The collaboration represents a convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing to develop advanced precision medicine diagnostic solutions. Caris has created a large-scale, multimodal clinico-genomic database and computing capability designed to analyze and unravel the molecular complexity of disease.
This platform provides differentiated capabilities for early detection, diagnosis, monitoring, therapy selection and drug development, positioning the collaboration to address significant gaps in current cancer treatment options for solid tumors.